Programs
- M. Tech. in Automotive Engineering -
- Fellowship In Interventional Pulmonology and Pulmonary Critical care - Fellowship
Publication Type : Journal Article
Source : Anti-Cancer Agents in Medicinal Chemistry. 2022 Apr 18. doi: 10.2174/1871520622666220418115310. Epub ahead of print. PMID: 35440316.
Url : https://pubmed.ncbi.nlm.nih.gov/35440316/
Campus : Kochi
School : School of Pharmacy
Department : Pharmacognosy
Year : 2022
Abstract : Objectives Hepatocellular carcinoma (HCC) is the sixth most common type of cancer and accounts for ~90% of cases with an approximated incidence of >1 million cases by 2025. Currently, the backbone of HCC therapy is the oral multi-kinase inhibitor, Sorafenib, which consists of a Pyridine heterocycle ring system. This review highlights the introspective characteristics of seven anticancer drugs of heterocyclic nature against HCC along with their structural activity relationships and molecular targets. Methods Literature collection was performed using databases such as PubMed, Google Scholar, SCOPUS, and Cross ref. Additional information was taken from the official website of FDA and GLOBOCAN. Key findings/ Results Based on the available literature, approved heterocyclic compounds showing promising results against HCC including Sorafenib (Pyridine), Regorafenib (Pyridine), Lenvatinib (Quinoline), Cabozantinib (Quinoline), Gemcitabine (Pyrimidine), 5-Fluorouracil (Pyrimidine)and Capecitabine (Pyrimidine), their mechanism of action and key aspects regarding its structural activity were included in the review. Conclusion Heterocyclic compounds represent almost two-thirds of the novel drugs approved by FDA between 2010 and 2020 against Cancer. This review summarizes the clinical relevance, mechanism of action, structural activity relationship, and challenges of the seven available anticancer drugs with heterocyclic ring systems against HCC.
Cite this Research Publication : Kumar AR, L A, Nair B, Mathew B, Sugunan S, Nath LR. Decoding the mechanism of drugs of heterocyclic nature against hepatocellular carcinoma. Anti-Cancer Agents in Medicinal Chemistry. 2022 Apr 18. doi: 10.2174/1871520622666220418115310. Epub ahead of print. PMID: 35440316.